Ramachandran A, Michael Mahesh K, Vijayan Panneerselvam, S V J Mani
{"title":"Multi-Modal Lung Cancer Detection Using Pyramidal Cascade Neuro-Fuzzy Fractional Network.","authors":"Ramachandran A, Michael Mahesh K, Vijayan Panneerselvam, S V J Mani","doi":"10.1080/07357907.2025.2520610","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer detection (LCD) is a process of identifying an occurrence of lung cancer (LC) or irregularities in the lungs. Early detection of lung cancer is crucial for improving patient survival and enabling effective treatment. Computed Tomography (CT) images and Positron emission tomography (PET) are employed for screening and detecting LC. These methods offer full cross-sectional images of the lungs to detect smaller lesions. Several techniques are developed for LCD, but they often fall into uncertainty. Therefore, a Pyramidal Cascade Neuro-Fuzzy Fractional Network (PCNFFN) is introduced for LCD utilizing CT and PET images. Initially, PET and CT images are pre-processed employing a Bilateral filter (BF). Then, lung lobes are segmented from both images utilizing Dual-Attention V-Network (DAV-Net). Thereafter, Black Hole Entropic Fuzzy Clustering (BHEFC) is employed to segment tumor locations from both lung lobe segmented images. Next, features are extracted from tumor location segmented images. Lastly, LCD is performed by PCNFFN. However, PCNFFN is a combination of Deep Pyramidal residual Network (PyramidNet) and Cascade Neuro-Fuzzy Network (NFN) with Fractional Calculus (FC). In addition, PCNFFN achieved an accuracy of about 91.002%, a true negative rate (TNR) of about 90.504% and a true positive rate (TPR) of about 92.571%.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"535-559"},"PeriodicalIF":1.9000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2025.2520610","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Lung cancer detection (LCD) is a process of identifying an occurrence of lung cancer (LC) or irregularities in the lungs. Early detection of lung cancer is crucial for improving patient survival and enabling effective treatment. Computed Tomography (CT) images and Positron emission tomography (PET) are employed for screening and detecting LC. These methods offer full cross-sectional images of the lungs to detect smaller lesions. Several techniques are developed for LCD, but they often fall into uncertainty. Therefore, a Pyramidal Cascade Neuro-Fuzzy Fractional Network (PCNFFN) is introduced for LCD utilizing CT and PET images. Initially, PET and CT images are pre-processed employing a Bilateral filter (BF). Then, lung lobes are segmented from both images utilizing Dual-Attention V-Network (DAV-Net). Thereafter, Black Hole Entropic Fuzzy Clustering (BHEFC) is employed to segment tumor locations from both lung lobe segmented images. Next, features are extracted from tumor location segmented images. Lastly, LCD is performed by PCNFFN. However, PCNFFN is a combination of Deep Pyramidal residual Network (PyramidNet) and Cascade Neuro-Fuzzy Network (NFN) with Fractional Calculus (FC). In addition, PCNFFN achieved an accuracy of about 91.002%, a true negative rate (TNR) of about 90.504% and a true positive rate (TPR) of about 92.571%.
期刊介绍:
Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.